MARKET TALK: Societe Generale Lifts AstraZeneca Price Target
2nd Jul 2010 13:54
1254 GMT [Dow Jones] Societe Generale lifts AstraZeneca (AZN.LN) price target to 3150p from 2850p after the company's Crestor patent win. Says all major US patent litigation has now been resolved in AstraZeneca's favor, with Crestor looking secure until '16, Nexium until '14 and Seroquel until '12.
Read moreUK MARKET TALK ROUNDUP: SHARES LOSING
1st Jul 2010 11:37
Stocks on the fall in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1037 GMT [Dow Jones] Charles Stanley upgrades AstraZeneca (AZN.LN) to accumulate from reduce following the company's victo
Read moreMARKET TALK: Charles Stanley Ups AstraZeneca To Accumulate
1st Jul 2010 11:37
1037 GMT [Dow Jones] Charles Stanley upgrades AstraZeneca (AZN.LN) to accumulate from reduce following the company's victory in the Crestor patent case. Says the decision removes overhang in the share price. "Investors should be aware of the significance of the ruling given that Crestor is without d
Read moreUPDATE: AstraZeneca Loses Bid To Overturn Antitrust Fine
1st Jul 2010 11:20
(Updates on AstraZeneca's bid to have fine overturned, adds detail.) By Mike Gordon and Carolyn Henson Of DOW JONES NEWSWIRES LUXEMBOURG (Dow Jones)--AstraZeneca PLC (AZN) Thursday lost its bid to overturn an antitrust fine imposed on the pharmaceuticals giant in 2005 for trying to squee
Read moreEU Court Cuts Astrazeneca Antitrust Fine To EUR52.5M Vs EUR60M
1st Jul 2010 08:52
LUXEMBOURG (Dow Jones)--A European Union court Thursday reduced an antitrust fine against AstraZeneca (AZN) and its Swedish subsidiary AstraZeneca AB for abusing their dominant position in the market by trying to prevent generic competition for ulcer drug Losec to EUR52.5 million from EUR60 million.
Read moreThursday's tips round-up: Hunting, Astra, Barclays
1st Jul 2010 06:51
Hunting's broad global spread should insulate it against turbulence related to the crisis in the Gulf. And despite a multiple of 26 times 2010 forecasts, the shares are off 33 per cent since their March peak. The market is arguably over-emphasising Hunting's risk from the Gulf and overlooking improv
Read moreOPTIONS REPORT: Traders See Anadarko Stuck In The Muck
30th Jun 2010 20:30
By Brendan Conway Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--On a day when investors retained some optimism over BP PLC's stock, options traders suggested that shares in Anadarko Petroleum Corp., a key partner in the Gulf oil spill, will stay depressed for several months. BP's stock ha
Read moreLondon close: Flat finish
30th Jun 2010 15:56
A jumpy start on Wall Street did nothing to steady a volatile Footsie, but despite all the fluctuations the leading index finished hardly changed on the day. London lost 272 points in June, the third monthly decline in a row, and traded a range of well over 400 points. Miners ENRC, Kazakhmys and A
Read moreFTSE 100 movers: Oil companies head higher
30th Jun 2010 15:29
Oil companies are back in favour today as investment banks try to generate fees by suggesting that BP could be taken over. JPMorgan Cazenove suggests Exxon Mobil as a potential suitor. Meanwhile, the FT says Anadarko, a 25% partner to BP on the Macondo prospect in the Gulf of Mexico, approved seve
Read moreTechMARK movers: AstraZeneca protects patents
30th Jun 2010 15:14
Anglo-Swedish drugs developer AstraZeneca has lost some of its early gains but it remains well up on the day after a favourable US court ruling in its battle to keep control of the patents to its best-selling cholesterol-lowering drug Crestor. The ruling means that cheaper, generic versions of Astr
Read moreLondon afternoon: Miners spoil the party
30th Jun 2010 14:15
The Footsie turned south over the lunch time session as traders took note of the US stock futures market which indicates US markets will open mixed and miners took a turn for the worse. Anglo-Swedish drugs giant AstraZeneca is still the best performer after it received a favourable US ruling in it
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
30th Jun 2010 12:35
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1135 GMT [Dow Jones] Morgan Stanley raises AstraZeneca (AZN.LN) price target to 3690p from 3540p following the company's v
Read moreMARKET TALK: Morgan Stanley Raises AstraZeneca Price Target
30th Jun 2010 12:35
1135 GMT [Dow Jones] Morgan Stanley raises AstraZeneca (AZN.LN) price target to 3690p from 3540p following the company's victory in the Crestor patent case. Says this is worth an extra 150p per share. Adds that while the defendants will no doubt appeal, the historical probability of success is only
Read moreBroker tips: Astra, Smiths Group, HMV
30th Jun 2010 12:23
Panmure Gordon has doffed its hat to AstraZeneca's legal eagles after the drugs giant's favourable verdict in a Delaware court on its CRESTOR patent. "The company's impressive record in intellectual property litigation continues with a win on Crestor to accompany wins on Prilosec, Pulmicort respul
Read moreLondon midday: Respectable gains for Footsie
30th Jun 2010 11:58
Gains in London are now approaching respectable, buoyed by strong demand for heavy hitters in the pharmaceuticals and energy sectors. Anglo-Swedish drugs giant AstraZeneca is the best performer after it received a favourable US ruling in its battle to keep control of the patents to its best-selling
Read more